167 related articles for article (PubMed ID: 28453754)
21. Probiotics for induction of remission in ulcerative colitis.
Kaur L; Gordon M; Baines PA; Iheozor-Ejiofor Z; Sinopoulou V; Akobeng AK
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD005573. PubMed ID: 32128795
[TBL] [Abstract][Full Text] [Related]
22. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
[TBL] [Abstract][Full Text] [Related]
23. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
24. Oral budesonide for induction of remission in ulcerative colitis.
Sherlock ME; MacDonald JK; Griffiths AM; Steinhart AH; Seow CH
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD007698. PubMed ID: 26497719
[TBL] [Abstract][Full Text] [Related]
25. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis.
Tong JL; Huang ML; Xu XT; Qiao YQ; Ran ZH
J Dig Dis; 2012 Apr; 13(4):200-7. PubMed ID: 22435504
[TBL] [Abstract][Full Text] [Related]
26. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
27. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
[TBL] [Abstract][Full Text] [Related]
28. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
29. Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?
Lakatos PL
World J Gastroenterol; 2009 Apr; 15(15):1799-804. PubMed ID: 19370774
[TBL] [Abstract][Full Text] [Related]
30. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
Rubin DT; Bradette M; Gabalec L; Dobru D; Márquez J; Inglis S; Magee E; Solomon D; D'Haens G;
J Crohns Colitis; 2016 Aug; 10(8):925-33. PubMed ID: 26908939
[TBL] [Abstract][Full Text] [Related]
31. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
32. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
33. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
[TBL] [Abstract][Full Text] [Related]
35. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.
Farup PG; Hinterleitner TA; Lukás M; Hébuterne X; Rachmilewitz D; Campieri M; Meier R; Keller R; Rathbone B; Oddsson E
Inflamm Bowel Dis; 2001 Aug; 7(3):237-42. PubMed ID: 11515850
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis.
Carmody JK; Plevinsky J; Peugh JL; Denson LA; Hyams JS; Lobato D; LeLeiko NS; Hommel KA
Aliment Pharmacol Ther; 2019 Oct; 50(8):911-918. PubMed ID: 31373712
[TBL] [Abstract][Full Text] [Related]
38. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R
Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445
[TBL] [Abstract][Full Text] [Related]
39. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Rembacken BJ; Snelling AM; Hawkey PM; Chalmers DM; Axon AT
Lancet; 1999 Aug; 354(9179):635-9. PubMed ID: 10466665
[TBL] [Abstract][Full Text] [Related]
40. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
